Lung: TroFuse-007 (MK2870-007)

A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer with PD-L1 TPS Greater than or Equal to 50%